El interés en corto de Humacyte da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Humacyte. Los datos de interés en corto se actualizan cada dos semanas.

Humacyte (NASDAQ:HUMA) Bolsa, Informe de interés en corto

HUMACYTE INC

Humacyte

Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Advanced Organ Systems, Advanced Tissue Constructs.

GameStop Corp.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

BHIL

BSGM

CISO

CLEU

GDHG

HUMA

IMTE

NYXH

ORKA

PTPI

RAPP

SURG

THTX

TXMD

WINT

ZYBT

El premercado de hoy revela fuertes movimientos bursátiles tras informes financieros y aprobaciones clave en sectores críticos.

Las acciones de GameStop (GME) suben alrededor del 13%; Aquí están 20 acciones que se mueven en el premercado

AADI

APTO

CADL

CARA

MESO

MOBX

MTEM

NVNI

OCEA

PRFX

QUBT

ZCAR

FedEx sube un 8,7% con resultados sólidos y una nueva estrategia. Descubre otras acciones destacadas en premercado hoy.

Las acciones de FedEx (FDX) suben alrededor de un 9%; 20 acciones que se mueven en premercado

Earnings

Equities

Futures

Economics

Federal Reserve

Los futuros caen ante la &#34;Triple Brujería&#34; y nuevos datos de inflación. ¿Qué dicen los analistas sobre el mercado?

Futuros de EE.UU. caen antes de datos clave de inflación y Triple Brujería

Seaport Global analyst Scott Graham initiates coverage on Ralliant (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RAL#NYSE">RAL</a>) with a Neutral rating.

Initiation

Analyst Ratings

Seaport Global Initiates Coverage On Ralliant with Neutral Rating

CELC

Celcuity Expects To Announce Topline Data For PIK3CA Wild-Type Cohort Of VIKTORIA-1 Clinical Trial In Q3 2025; Expects To Report Topline Data For PIK3CA Mutant Cohort In Q4 2025

Celcuity Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELC#NASDAQ">CELC</a>), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the issuance of U.S. Patent No. 12,350,276 covering the clinical dosing regimen for its lead drug candidate, gedatolisib, in ER+/HER2- breast cancer patients. The patent extends Celcuity's patent exclusivity in the U.S. into 2042.
Celcuity expects to announce topline data for the PIK3CA wild-type cohort of the VIKTORIA-1 clinical trial in the third quarter of 2025 and to report topline data for the PIK3CA mutant cohort in the fourth quarter of 2025.

Celcuity Announces Issuance Of U.S. Patent Covering Clinical Dosing Regimen For Gedatolisib In ER+/HER2- Breast Cancer Patients, Extending Celcuity's Patent Exclusivity In U.S. Into 2042

DCOM

Dime Adds Fifth Vertical With Lender Finance, Deepening Focus On Private Equity And Private Credit Clients

Celcuity Granted New U.S. Patent For Gedatolisib Dosing Regimen, Extending Patent Exclusivity Through 2042

D. Boral Capital analyst Jason Kolbert maintains OS Therapies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/OSTX#AMEX">OSTX</a>) with a Buy and maintains $20 price target.

Price Target

OSTX

D. Boral Capital Maintains Buy on OS Therapies, Maintains $20 Price Target

I-Mab (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMAB#NASDAQ">IMAB</a>) (the "Company"), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab's management team will participate in the BTIG Virtual Biotechnology Conference, being held on July 29-30, 2025.
Conference details are as follows:
BTIG Virtual Biotechnology Conference Format: Fireside Chat and one-on-one meetings Date: Tuesday, July 29, 2025 Time: 10:00 AM ET Webcast Link: Available on the News &amp; Events page of the I-Mab website
The webcast of the event will be accessible from News &amp; Events page of the&nbsp;I-Mab&nbsp;website for 90 days.

IMAB

I-Mab to Join Virtual Biotech Event, Talks Cancer Treatment Progress With Investors

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Rxsight Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXST#NASDAQ">RXST</a>)</h3>
<ul class="wp-block-list">
<li>On July 8, RxSight cut its 2025 revenue guidance from $160 million–$175 million to $120 million–$130 million. &#8220;Guided by insights from our second quarter underperformance and building on our long-term vision, we are evolving our commercial approach to re-direct more of our focus toward supporting customer success within new and existing practices,&#8221; said Dr. Ron Kurtz, Chief Executive Officer and President of RxSight. The company's stock fell around 39% over the past five days and has a 52-week low of $6.32.</li>
<li>RSI Value: 20.9</li>
<li>RXST Price Action: Shares of Rxsight fell 5.4% to close at $8.00 on Friday.</li>
<li>Edge Stock Ratings: 1.77 Momentum score with Value at 73.93. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/rxst"><img loading="lazy" decoding="async" width="416" height="183" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/14070107/image-149.png" alt="" class="wp-image-983751" style="width:284px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/14070107/image-149.png 416w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/14070107/image-149-300x132.png 300w" sizes="(max-width: 416px) 100vw, 416px" /></a></figure>
<h3 class="wp-block-heading">Sarepta Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul class="wp-block-list">
<li>On June 25, HC Wainwright &amp; Co. downgraded the stock from Neutral to Sell and cut its price target on the stock from $40 to $10. The company's stock fell around 13% over the past month and <a href="https://www.benzinga.com/quote/SRPT">has a 52-week low</a> of $16.88.</li>
<li>RSI Value: 27</li>
<li>SRPT Price Action: Shares of Sarepta Therapeutics fell 4.7% to close at $18.17 on Friday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0714">SRPT stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0714"><img loading="lazy" decoding="async" width="935" height="861" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/14070217/image-150.png" alt="" class="wp-image-983752" style="width:627px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/14070217/image-150.png 935w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/14070217/image-150-300x276.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/14070217/image-150-768x707.png 768w" sizes="(max-width: 935px) 100vw, 935px" /></a></figure>
<h3 class="wp-block-heading">TransMedics Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>)</h3>
<ul class="wp-block-list">
<li>On May 8, TransMedics Group reported better-than-expected first-quarter financial results and raised its FY25 sales guidance above estimates. &#8220;Overall, we are very pleased with our first quarter performance, which we believe underscores the unique attributes of our business and the ability to deliver strong top and bottom-line financial results,&#8221; said Waleed Hassanein, MD, President and Chief Executive Officer. The company's stock fell around 21% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/TMDX">low of $55.00</a>.</li>
<li>RSI Value: 27.1</li>
<li>TMDX Ltd Price Action: Shares of TransMedics fell 9.9% to close at $112.46 on Friday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0714">TMDX shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0714"><img loading="lazy" decoding="async" width="888" height="832" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/14070534/image-151.png" alt="" class="wp-image-983758" style="width:667px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/14070534/image-151.png 888w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/14070534/image-151-300x281.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/14070534/image-151-768x720.png 768w" sizes="(max-width: 888px) 100vw, 888px" /></a></figure>
Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and s<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">ee how they compare.</a>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46364472/top-3-real-estate-stocks-that-may-fall-off-a-cliff-this-month">Top 3 Real Estate Stocks That May Fall Off A Cliff This Month</a></li>
</ul>
Photo via Shutterstock

Long Ideas

RXST

SRPT

TMDX

Top 3 Health Care Stocks That Could Blast Off In July

First Community Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCCO#NASDAQ">FCCO</a>) ("First Community" or "FCCO"), the holding company of First Community Bank, and Signature Bank of Georgia (OTCPK: SGBG) ("Signature" or "SGBG") jointly announced today the signing of a definitive merger agreement, under which First Community has agreed to acquire Signature in an all-stock transaction with a total current value of approximately $41.6 million, based on First Community's closing price of $24.84 per share as of July 11, 2025. The transaction value at the time of the merger may change due to changes in the price of First Community stock.
On a pro forma combined basis, the combined company is expected to have approximately $2.3 billion in total assets, $2.0 billion in total deposits, and $1.5 billion in total loans at closing. The transaction will create a 23-office banking company with locations spanning the Midlands,&nbsp;Aiken, Upstate, and Piedmont Regions of South Carolina, the Augusta, Georgia area, and now the Atlanta-Sandy Springs-Roswell, Georgia MSA. The merger agreement has been unanimously approved by the Board of Directors of each company. Closing of the transaction, which is expected to occur early in the first quarter of 2026, is subject to customary conditions, including regulatory approval and approval by the shareholders of Signature and First Community.&nbsp;
Per the merger agreement, Signature shareholders will have the right to receive 0.6410 shares of First Community common stock for each share of Signature common stock. The merger is expected to enhance First Community's tangible common equity to tangible assets (TCE/TA) ratio by approximately 35&nbsp;basis points, resulting in a pro forma ratio of 7.45%. It is projected to be accretive to First Community's earnings per share by approximately 4.4% in 2026, the first year of combined operations. The transaction structure anticipates tangible book value dilution of approximately 2.6%, with an earnback period of 2.2 years. The internal rate of return on the deal is estimated at approximately 27.6%, reflecting the strong financial and strategic merits of the transaction.

FCCO

SGBG

First Community Agrees To Acquire Signature In All-Stock Transaction With Total Current Value Of ~$41.6M

Gastrointestinal biomarker tests enhance patient diagnosis of&nbsp;IBD and pancreatic insufficiency on leading clinical chemistry platforms

QDEL

QuidelOrtho And BÜHLMANN Expand Access To Fecal Biomarker Testing With Integration Of Turbo Assays On VITROS Platforms

Hedge Funds

General

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

ASL Strategic Value Fund Urdes Avadeln Shareholders To Vote Against All Director Nominees, Calls For Independent Oversight Of Annual Meeting Vote

Positive high-level results from the BaxHTN Phase III trial showed baxdrostat at two doses (2mg and 1mg) demonstrated a statistically significant and clinically meaningful reduction in mean seated systolic blood pressure (SBP) compared with placebo at 12 weeks. The trial also successfully met all secondary endpoints. Patients with uncontrolled or treatment resistant hypertension received baxdrostat or placebo on top of standard of care. Baxdrostat was generally well tolerated with a favorable safety profile.
There are 1.3 billion people worldwide living with hypertension.1 When uncontrolled, hypertension can lead to a higher risk of heart attack, stroke, heart failure and kidney disease.2,3 In the US, approximately 50% of hypertensive patients who are on multiple treatments do not have their blood pressure under control.4 Growing evidence points to aldosterone dysregulation as one of the key biological drivers of hypertension.5,6
Dr. Bryan Williams, Chair of Medicine at University College London, primary investigator, said: "Many people continue to struggle with high blood pressure that is hard to control, even when taking multiple medications. The highly promising BaxHTN Phase III results show that once-daily baxdrostat on top of standard of care can meaningfully lower systolic blood pressure and offer a potential new treatment approach for controlling hypertension, the leading risk factor for cardiovascular disease."
Sharon Barr, Executive Vice President, BioPharmaceuticals R&amp;D, said: "We are very excited with the BaxHTN Phase III results, which show statistically significant and clinically meaningful reductions in systolic blood pressure. These findings provide compelling evidence of baxdrostat's potential to address a critical unmet need by targeting aldosterone dysregulation, bringing a novel mechanism to a field that has seen little innovation in over two decades."
BaxHTN is a Phase III, multicenter, randomized, double-blinded, placebo-controlled, parallel group study to evaluate the safety, tolerability and effect of baxdrostat in patients with uncontrolled hypertension being treated with two different antihypertensive medications and patients with resistant hypertension being treated with three or more different antihypertensive medications, one of which is a diuretic.7
The data will be shared with regulatory authorities around the world and presented in a late‑breaking Hot Line session at the European Society of Cardiology (ESC) Congress in August 2025.
Baxdrostat is a potential first-in-class, highly selective aldosterone synthase inhibitor (ASI) that targets the hormone driving elevated blood pressure and increased cardiovascular and renal risk. It is currently being investigated in clinical trials as a monotherapy for hypertension8,9 and primary aldosteronism,10 and in combination with dapagliflozin for chronic kidney disease and the prevention of heart failure in high-risk hypertensive patients.11-13

AstraZeneca's New Drug Baxdrostat Significantly Lowers Blood Pressure in Late-Stage Trial

Mr. Velasquez most recently served as Vice President Global Finance Transformation at 3M Company. Prior to that, Mr. Velasquez held several senior finance roles at 3M, including Vice President Global Finance and CFO Manufacturing &amp; Supply Chain Operations, and Vice President Global Finance and CFO Consumer Business, as well as serving as the Finance Director and Country CFO at 3M Russia and 3M Colombia.&nbsp;

Stepan Names Ruben Velasquez As New Vice President And Chief Financial Officer

Bio-Techne Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>) today announced that its Simple Western&#x2122; Technology played a key role in supporting the FDA approval of ZEVASKYN&#x2122; (prademagene zamikeracel), the first autologous cell-based gene therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB), developed by Abeona Therapeutics&#xAE; (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABEO#NASDAQ">ABEO</a>). Throughout clinical development, Simple Western enabled precise identification and quantification of Collagen VII, a complex therapeutic target critical to ZEVASKYN's potency, supporting lot release testing for the viral vector and the cell therapy in a GMP setting.
Abeona selected Simple Western over competing methods like traditional western blot for its speed, reproducibility, picogram-level sensitivity, and minimal sample volume requirements. The platform effectively detected both the trimeric and monomeric forms of Collagen VII, addressing the analytical challenges posed by the protein's size and structure and supporting the regulatory requirements for potency and consistency.

ABEO

TECH

Bio-Techne's Simple Western Technology Utilized In FDA Approval Of ZEVASKYN, Developed By Abeona Therapeutics

Redwire Announces Edge Autonomy Stalker Uncrewed Aerial System Added To Department of Defense's Blue List of Approved Drones

CollPlant Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLGN#NASDAQ">CLGN</a>), a regenerative and aesthetics medicine company developing disruptive technologies and products based on its non-animal-derived recombinant human collagen (rhCollagen), today announced the appointment of Bowman Bagley as Vice President, Commercial North America. In this newly created role, Mr. Bagley will lead the company's commercial strategy and execution in North America, including sales and marketing, logistics, and expansion of market presence for CollPlant's rhCollagen-based products and platforms.
 &nbsp;

CLGN

CollPlant Taps Bowman Bagley to Lead North American Push for Skin and Tissue Tech

Biotech

Bio-Techne Says Its Simple Western Technology Played A Role In Supporting FDA Approval Of Abeona's ZEVASKYN

WKHS

Workhorse Is Currently In Discussions With A Privately Held US-Based Manufacturer Of Electric Commercial Vehicles About A Potential Transaction In Which The Manufacturer Would Be Merged Into A Newly Created Subsidiary Of The Company In Exchange For Newly Issued Shares Of The Company's Common Stock

Aurora Cannabis' Distribution Centre In Brampton, Ontario, Granted EU-GMP Certification, Increasing Company's International Export Capabilities

Goldman Sachs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) has initiated coverage on Nebius Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIS#NASDAQ">NBIS</a>) with a Buy rating and a price target of $68. This suggests a potential upside of about 53.49% from the stock&#8217;s closing price on Friday.
What Happened: Goldman Sachs identified Nebius as a major player in the AI Neocloud market, offering AI GPU infrastructure rental services that support the fast-growing Generative AI sector, <a href="https://www.investing.com/news/analyst-ratings/goldman-sachs-initiates-nebius-group-stock-with-buy-rating-68-target-93CH-4132970">reported</a> Investing.com.
The investment bank emphasized Nebius's key strengths, including its comprehensive software suite, cost efficiency, and proven ability to operate at scale—advantages that set it apart from other GPU rental providers. While the stock has seen recent gains, Goldman Sachs believes Nebius's AI infrastructure business is still undervalued relative to its industry peers.
See Also: <a href="https://benzinga.com/news/topics/25/07/46384959/faa-boeing-say-fuel-switch-locks-on-787-dreamliner-are-safe-amid-air-india-crash-probe" target="_blank" rel="noopener">FAA, Boeing Say Fuel Switch Locks On 787 Dreamliner Are Safe Amid Air India Crash Probe</a>
Goldman Sachs anticipates a "supportive catalyst path" over the next 12 months, which it believes will drive further stock outperformance and reinforce the firm's positive risk-reward outlook.
Why It Matters: Nebius Group has been making significant strides in the AI industry. The company&#8217;s stock has seen a staggering <a href="https://www.benzinga.com/content/46375205/nebius-group-up-385-analysts-say-its-still-a-bargain">385% year-over-year revenue growth</a> in its latest quarter. In the first quarter of 2025, the company posted revenues of $55.3 million, marking a 385% increase compared to the same period last year.
Nebius Group is among the earliest adopters of Nvidia Corp.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) full-stack approach to <a href="https://www.benzinga.com/content/45993702/why-nebius-group-is-one-of-the-top-ai-stocks-to-watch">AI infrastructure</a> and is a Reference Platform NVIDIA Cloud Partner.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://benzinga.com/news/politics/25/07/46383817/jeffrey-epstein-in-tapes-released-by-michael-wolff-i-was-donalds-closest-friend" target="_blank" rel="noopener">Jeffrey Epstein in Tapes Released by Michael Wolff: &#8216;I Was Donald&#8217;s Closest Friend&#8217;</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo: Shutterstock

Tech

NBIS

NVDA

Goldman Sachs Sees 53% Upside In Nebius Group, Calls AI Infrastructure 'Undervalued'

Financing

Press Releases

Humacyte, Inc. Announces Proposed Public Offering of Common Stock

Humacyte, Inc. Announces Pricing of Public Offering of Common Stock

Humacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 28, 2025

Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update

Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 13, 2025

Humacyte Announces First Quarter 2025 Financial Results and Provides Business Update

Humacyte to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq

Humacyte Clinical Results in High-Risk Dialysis Patients from V007 Pivotal Phase 3

Health Care

Results from Humacyte's V007 Pivotal Phase 3 AV Access Study Highlighted by Presentation at the Society for Vascular Surgery Meeting

Comments

Humacyte

Interés en corto

Humacyte (NASDAQ:HUMA) Bolsa, Informe de interés en corto

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL